Stockreport

Avidity gets FDA partial clinical hold lifted on DM1 drug candidate [Seeking Alpha]

Avidity Biosciences, Inc.  (RNA) 
PDF known as del-desiran and AOC 1001, for the treatment of myotonic dystrophy type 1, or DM1. The therapy is being evaluated in an ongoing Phase 3 study called HARBOR. [Read more]